HR19042 Capsule, Tarpeyo®, Budenofalk®
Phase 1Completed 2 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary IgA Nephropathy; Autoimmune Hepatitis
Conditions
Primary IgA Nephropathy; Autoimmune Hepatitis
Trial Timeline
Dec 27, 2023 → Jan 25, 2024
NCT ID
NCT06922305About HR19042 Capsule, Tarpeyo®, Budenofalk®
HR19042 Capsule, Tarpeyo®, Budenofalk® is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for Primary IgA Nephropathy; Autoimmune Hepatitis. The current trial status is completed. This product is registered under clinical trial identifier NCT06922305. Target conditions include Primary IgA Nephropathy; Autoimmune Hepatitis.
What happened to similar drugs?
20 of 20 similar drugs in Primary IgA Nephropathy; Autoimmune Hepatitis were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06922305 | Phase 1 | Completed |
Competing Products
20 competing products in Primary IgA Nephropathy; Autoimmune Hepatitis